V
Vlastimil Hrabal
Economist
1
APPEARANCES
1
PODCASTS
012
DEC 30
JAN 6
JAN 13
JAN 20
JAN 27
FEB 3
FEB 10
FEB 17
FEB 24
MAR 3
MAR 10
MAR 17
MAR 24
MAR 31
APR 7
APR 14
APR 21
APR 28
MAY 5
MAY 12
MAY 19
MAY 26
JUN 2
JUN 9
JUN 16
JUN 23
JUN 30
JUL 7
JUL 14
JUL 21
JUL 28
AUG 4
AUG 11
AUG 18
AUG 25
SEP 1
SEP 8
SEP 15
SEP 22
SEP 29
OCT 6
OCT 13
OCT 20
OCT 27
NOV 3
NOV 10
NOV 17
NOV 24
DEC 1
DEC 8
DEC 15
DEC 22
DEC 29
JAN 5
JAN 12
JAN 19
JAN 26
FEB 2
FEB 9
FEB 16
FEB 23
MAR 2
MAR 9
MAR 16
MAR 23
MAR 30
APR 6
APR 13
APR 20
APR 27
MAY 4
MAY 11
MAY 18
MAY 25
JUN 1
JUN 8
JUN 15
JUN 22
JUN 29
JUL 6
JUL 13
JUL 20
JUL 27
AUG 3
AUG 10
AUG 17
AUG 24
AUG 31
SEP 7
SEP 14
SEP 21
SEP 28
Jul 31, 2026
The Hospital Gold Standard Catches Just 5% of Arrhythmias with Vlastimil Hrabal
12:42
12:57
13:08
21:12

Jordan BurginHOST
How has that looked and what kind of things have you had to show them before they started trusting the output?

Vlastimil HrabalGUEST
We are able to find, as I mentioned, with this solution, 10 times higher number of detections than whatever is currently available on the market and as a golden standard in the hospitals.

Vlastimil HrabalGUEST
so we are helping them to detect more cases that they can take care of and prevent the stroke and heart failure and early onset of dementia of course we need to prove clinical studies which we have done so the last clinical study we done last year with the university hospitals in czech republic we have 98 specificity are interested in this in this number means that when we say it's arithmeia most probably uh 100 true we have very less positive cases it's around 0.001 um so that's also important that we don't add the workers and we don't care the patients with fast positive cases and this is also about the efficiency of the doctors in the doctor's office or physicians Because most of the time, the people waiting in the doctor's office, waiting room, it's about the feelings of doctor.
7 MINS LATER

Jordan BurginHOST
How are you now going to get it to market? Because I believe you're going a different route in commercialization than most companies typically would.